Skip to main content

Advertisement

Table 4 Incremental cost-effectiveness ratios (ICERs) and probabilities of each intervention being the most cost effective at various willingness-to-pay thresholds

From: The impact of incorporating Bayesian network meta-analysis in cost-effectiveness analysis - a case study of pharmacotherapies for moderate to severe COPD

Intervention Meta-analysis ICER Probability of being cost-effective by willingness-to-pay threshold
$30,000/QALY $50,000/QALY $70,000/QALY $100,000/QALY
Placebo as reference
Placebo PTC Reference 35% 10% 3% 0%
MTC Reference 37% 12% 3% 2%
ICS PTC 27044 40% 42% 38% 31%
MTC 27614 49% 55% 44% 31%
LABA PTC 65509 1% 6% 6% 5%
MTC 64339 1% 2% 1% 0%
ICS + LABA PTC 57933 1% 6% 11% 18%
MTC 52116 0% 7% 1% 29%
LAMA PTC 38427 21% 34% 43% 46%
MTC 41203 13% 24% 35% 38%
ICS as reference
LABA PTC Dominated -- -- -- --
  MTC Dominated -- -- -- --
ICS + LABA PTC 89843 -- -- -- --
  MTC 96749 -- -- -- --
LAMA PTC 25930 -- -- -- --
  MTC 57854 -- -- -- --